Quince Therapeutics (QNCX) Short term Debt (2023 - 2025)
Quince Therapeutics (QNCX) posted quarterly Short term Debt of $12.4 million for Q4 2025, down 29.4% quarter-over-quarter from $17.5 million in Q3 2025.
Quince Therapeutics (QNCX) Short term Debt (2023 - 2025) Analysis & Trends
Quince Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $12.4 million for Q4 2025.
- In Q4 2025, Short term Debt changed N/A year-over-year to $12.4 million; the TTM figure through Dec 2025 stood at $12.4 million (changed N/A YoY), while the FY2025 annual figure was $12.4 million, changed N/A from the prior year.
- Short term Debt for Q4 2025 stood at $12.4 million, down from $17.5 million in the prior quarter.
- The five-year high for Short term Debt was $17.5 million in Q3 2025, with the low at $4.1 million in Q4 2023.
- The 3-year median for Short term Debt is $5.0 million (2024), against an average of $8.7 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.37 Mn |
| Sep 30, 2025 | 17.52 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Dec 31, 2023 | 4.10 Mn |